The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Recurrence and disease-specific survival after 10-year disease-free interval in patients with primary retroperitoneal liposarcoma: Implications for long-term surveillance.
 
Mark Archer Eckardt
No Relationships to Disclose
 
Danielle S. Graham
No Relationships to Disclose
 
Brian E. Kadera
No Relationships to Disclose
 
Kyle D. Klingbeil
No Relationships to Disclose
 
Scott D. Nelson
No Relationships to Disclose
 
Sarah M. Dry
No Relationships to Disclose
 
Anusha Kalbasi
No Relationships to Disclose
 
Arun S. Singh
Stock and Other Ownership Interests - AntiCancer; Certis Oncology Solutions
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Lilly
Speakers' Bureau - Daiichi Sankyo; Deciphera; Eisai; Lilly; MJH Life Sciences; Novartis; Scripps Health
Research Funding - Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); deciphera (Inst); Lilly (Inst); Nanocarrier (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Deciphera; Eisai; Lilly; Novartis
Other Relationship - Certis Oncology Solutions
 
Bartosz Chmielowski
Consulting or Advisory Role - Deciphera; Epizyme; Genentech; IDEAYA Biosciences; Iovance Biotherapeutics; Nektar; OncoSec; Sanofi
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Advenchen Laboratories (Inst); Aeglea Biotherapeutics (Inst); Array BioPharma (Inst); Ascentage Pharma (Inst); Atreca (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); IDEAYA Biosciences (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Neon Therapeutics (Inst); Novartis (Inst); PACT Pharma (Inst); RAPT Therapeutics (Inst); Replimune (Inst); Rgenix (Inst); Tolero Pharmaceuticals (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Deciphera; Epizyme; Regeneron
 
Frederick R. Eilber
No Relationships to Disclose
 
Joseph G. Crompton
No Relationships to Disclose
 
Frederick C. Eilber
Stock and Other Ownership Interests - Certis Oncology Solutions